Search Orphan Drug Designations and Approvals
-
Generic Name: | C1 esterase inhibitor (human) | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Cinryze | ||||||||||||||||
Date Designated: | 07/16/2004 | ||||||||||||||||
Orphan Designation: | Treatment of angioedema | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Takeda Development Center Americas, Inc. 95 Hayden Avenue Lexington, Massachusetts 02421 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | C1 esterase inhibitor (human) |
---|---|---|
Trade Name: | Cinryze | |
Marketing Approval Date: | 10/10/2008 | |
Approved Labeled Indication: | Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE) | |
Exclusivity End Date: | 10/10/2015 | |
Exclusivity Protected Indication* : | ||
2 | Generic Name: | C1 esterase inhibitor (human) |
---|---|---|
Trade Name: | Cinryze | |
Marketing Approval Date: | 06/20/2018 | |
Approved Labeled Indication: | CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE). | |
Exclusivity End Date: | 06/20/2025 | |
Exclusivity Protected Indication* : | CINRYZE (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in pediatric patients ages 6-11 with Hereditary Angioedema (HAE). | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-